Durect corporation reports first quarter 2025 financial results and provides business update

Planning a registrational phase 3 trial for larsucosterol in alcohol-associated hepatitis (ah) with topline results expected within two years of trial initiation larsucosterol phase 2b ahfirm trial results published in nejm evidence in january 2025 cupertino, calif. , may 13, 2025 /prnewswire/ -- durect corporation (nasdaq: drrx) today announced financial results for the first quarter ended march 31, 2025 and provided a business update.
DRRX Ratings Summary
DRRX Quant Ranking